Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States

S Barua, R Greenwald, J Grebely, GJ Dore… - Annals of internal …, 2015 - acpjournals.org
The aim of this study was to systematically evaluate state Medicaid policies for the treatment
of hepatitis C virus (HCV) infection with sofosbuvir in the United States. Medicaid …

Direct-acting antiviral agents for HCV infection affecting people who inject drugs

J Grebely, B Hajarizadeh, GJ Dore - Nature reviews Gastroenterology & …, 2017 - nature.com
Globally, 12 million people are estimated to have injected drugs in the past year, 50% of
whom have chronic HCV infection, with people who have previously injected drugs …

[HTML][HTML] EASL Clinical Practice Guidelines: management of hepatitis C virus infection

European Association For The Study Of The Liver - Journal of hepatology, 2014 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide. The long-term impact of HCV infection is highly variable, from minimal changes …

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

J Grebely, O Dalgard, B Conway… - The lancet …, 2018 - thelancet.com
Background Despite revised guidelines that no longer exclude people who inject drugs
(PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to …

Recommendations for the management of hepatitis C virus infection among people who inject drugs

J Grebely, G Robaeys, P Bruggmann, A Aghemo… - International Journal of …, 2015 - Elsevier
In high income countries, the majority of new and existing hepatitis C virus (HCV) infections
occur among people who inject drugs (PWID). In many low and middle income countries …

The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for …

NK Martin, P Vickerman, GJ Dore… - Current opinion in HIV …, 2015 - journals.lww.com
The hepatitis C virus epidemics in key populations (includin... : Current Opinion in HIV and AIDS
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners …

[HTML][HTML] Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a …

K Mason, Z Dodd, M Guyton, P Tookey, B Lettner… - International Journal of …, 2017 - Elsevier
Background Direct acting antiviral (DAA) treatments for Hepatitis C (HCV) are now widely
available with sustained virologic response (SVR) rates of> 90%. A major predictor of …

Challenges facing a rural opioid epidemic: treatment and prevention of HIV and hepatitis C

AJ Schranz, J Barrett, CB Hurt, C Malvestutto… - Current hiv/aids …, 2018 - Springer
Abstract Purpose of Review This article reviews recent epidemiologic trends in HIV and
hepatitis C virus (HCV) and strategies for treatment and prevention of these infections as …

The removal of DAA restrictions in Europe–one step closer to eliminating HCV as a major public health threat

AD Marshall, JM Pawlotsky, JV Lazarus, A Aghemo… - Journal of …, 2018 - Elsevier
Of∼ 10.2 million people with chronic HCV infection in Europe, 6.7 million live in Eastern
Europe, 2.3 million in Western Europe and 1.2 million in Central Europe. HCV transmission …

Hepatitis C: the beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe

GV Papatheodoridis, A Hatzakis… - Journal of viral …, 2018 - Wiley Online Library
Hepatitis C virus (HCV) infection is a major public health problem in the European Union
(EU). An estimated 5.6 million Europeans are chronically infected with a wide range of …